Awakn Life Sciences ( (TSE:AWKN) ) has provided an update.
Awakn Life Sciences Corp. has provided an update on its R&D programs focusing on therapies for Alcohol Use Disorder (AUD) and PTSD. The company’s lead program, AWKN-001, is in Phase 3 trials in the UK for treating severe AUD, with potential market exclusivity if successful. AWKN-002, an oral thin film formulation of esketamine for AUD, has completed mechanistic studies and a Pre-IND meeting with the FDA, setting the stage for a Phase 2b trial in 2026. These developments position Awakn to potentially secure market exclusivity and strengthen its foothold in the treatment of AUD, reflecting significant progress in its strategic R&D efforts.
More about Awakn Life Sciences
Awakn Life Sciences Corp. is a clinical-stage biotechnology company focused on developing therapeutics for substance use and mental health disorders.
YTD Price Performance: 0%
Average Trading Volume: 26,558
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.75M
Find detailed analytics on AWKN stock on TipRanks’ Stock Analysis page.